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Background: We evaluated the prognostic value of volume-based metabolic positron emission tomography
(PET) parameters in patients with small cell lung cancer (SCLC) compared with other factors.
Methods: The subjects were 202 patients with pathologically proven SCLC who underwent pretreatment
18F-fluorodeoxyglucose (FDG) PET/computed tomography (CT). Volumetric metabolic parameters of intrathoracic
malignant hypermetabolic lesions, including maximum and average standardized uptake value, sum of
metabolic tumor volume (MTV), and sum of total lesion glycolysis (TLG) were measured.
Results: 164 patients had died during follow-up (median 17.4 months) and median overall survival was 14 months.
On univariate survival analysis, age, stage, treatmentmodality, sum of MTV (cutoff = 100 cm3), and sum of TLG (cutoff = 555)
were significant predictors of survival. There was a very high correlation between the sum of MTV and the sum of TLG
(r = 0.963, P < 0.001). On multivariate survival analysis, age (HR = 1.04, P < 0.001), stage (HR = 2.442, P < 0.001), and sum
of MTV (HR = 1.662, P = 0.002) were independent prognostic factors. On subgroup analysis based on limited disease
(LD) and extensive disease (ED), sum of MTV and sum of TLG were significant prognostic factors only in LD.
Conclusion: Both sum of MTV and sum of TLG of intrathoracic malignant hypermetabolic lesions are important
independent prognostic factors for survival in patients with SCLC, in addition to age and clinical stage. However, it may
be more useful in limited disease rather than in extensive disease.
Keywords: Small cell lung cancer, [18F]FDG-PET/CT, Metabolic tumor volume, Total lesion glycolysis, PrognosisBackground
In 2008, an estimated 1,608,800 new lung cancer cases
were diagnosed globally, and there were 1,378,400 esti-
mated deaths [1]. Small cell lung cancer (SCLC), which
accounts for 13% of all lung cancer [2], is distinct from
non-SCLC due to its rapid doubling time, high growth
fraction, and early development of widespread metastases.* Correspondence: jynm.choi@samsung.com
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unless otherwise stated.However, despite high initial responses to therapy, most
patients die from recurrent disease [3]. Clinical stage at
initial presentation is the most powerful prognostic factor
of SCLC, with other factors including performance status,
age, gender, lactate dehydrogenase (LDH), and albumin [4].
The simple two-stage system of the Veterans Adminis-
tration Lung Study Group is generally accepted in SCLC,
which classifies cases as limited disease (LD; primary
tumor and nodal involvement limited to one hemi-
thorax) and extensive disease (ED; inoperable patients
who cannot be classified as having LD) depending
mainly on whether all known tumors could be treated. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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care in patients of good performance status with LD is
concurrent chemotherapy and radiotherapy followed by
prophylactic cranial irradiation in those responding to
treatment. The mainstay of treatment for ED is palliative
chemotherapy. Because of the differences in treatment
strategies and prognoses of patients with LD and ED, ac-
curate staging to select the appropriate treatment for an
individual patient is of paramount importance [6]. How-
ever, current prognostic evaluations are still controver-
sial, and the two-stage system is unsatisfactory in terms
of predicting prognosis [5,7]. For example, ipsilateral
pleural effusion and contralateral mediastinal or supra-
clavicular lymph node metastases are neither precisely
defined nor uniformly handled by investigators, which
may have high prognostic impact [5]. Therefore, more
discriminative prognostic markers are necessary to select
the appropriate treatment and to properly predict treat-
ment outcomes and survival.
In SCLC, [18F]fluorodeoxyglucose-positron emission
tomography (FDG-PET) has emerged as an essential im-
aging tool for staging, impact on patient management,
and early evaluation of treatment response [8-15], and
FDG-PET findings have been suggested as useful prog-
nostic indicators [16-19]. While volumetric metabolic
parameters, such as metabolic tumor volume (MTV) or
total lesion glycolysis (TLG) have been reported to be
independent prognostic factors in other types of malig-
nancies [19-27], only two studies have evaluated the
volumetric metabolic parameters in patients with SCLC
[19,26]. These studies used the volumetric parameters of
all hypermetabolic lesions in the whole body, which may
be time-consuming and not practical for routine prac-
tice. In addition, they used a fixed threshold standard-
ized uptake value (SUV) of 2.5 or 3.0. In this setting, it
may be difficult to measure the TLG or MTV of lesions
within the organs with relatively high physiological FDG
uptake, such as the brain, liver, or bone marrow. An-
other potential limitation of previous studies has been
the relatively small number of subjects. Therefore, we
evaluated the prognostic value of volumetric metabolic
parameters measured in intrathoracic lesions by FDG-
PET/computed tomography (CT) in patients with SCLC
and compared them with other prognostic parameters.
Methods
Subjects
We retrospectively reviewed the medical records of all
219 patients with pathologically proven SCLC who
underwent pretreatment with FDG-PET/CT at the Sam-
sung Medical Center, Sungkyunkwan University School
of Medicine, between May 2003 and December 2009.
Among them, patients who refused the treatment and
were not followed up after diagnosis in our institutionwere excluded from further analysis, and the remaining
202 patients, who underwent any kinds of therapy in
our institution, were included. All patients with SCLC
underwent complete blood cell counts and chemistry
panels, CT of the chest and upper abdomen, brain mag-
netic resonance imaging, bronchoscopy and FDG-PET/
CT as a staging workup. Bone scintigraphy, abdominal
or neck CT scan, abdominal ultrasonography, and neck
ultrasonography were performed when clinically indi-
cated. All staging workups were completed before initial
therapy. Our institutional review board approved the
study protocol (Samsung Medical Center IRB).
[18F] Fluorodeoxyglucose-positron emission tomography/
computed tomography
All subjects fasted for at least 6 hours before the PET/
CT scans. Blood glucose levels at the time of injection
of FDG were lower than 200 mg/dl in all patients. PET/
CT scans were performed on two different dedicated
PET/CT scanners (Discovery LS or Discovery STE; GE
Healthcare, Milwaukee, WI, USA). Among the 202 pa-
tients, scans in 140 were performed using the Discovery
LS PET/CT scanner and scans in 62 patients were per-
formed using the Discovery STE PET/CT scanner. No
intravenous or oral contrast materials were used.
In the Discovery LS scanner, whole-body CT was per-
formed using a continuous spiral technique with an
8-slice helical CT (140 kV, 40–120 mAs adjusted to the
patient’s body weight, section width of 5 mm) 45 minutes
after the injection of approximately 370 MBq FDG. After
the CT scans were complete, emission scans were ob-
tained from the thigh to the head for 4 minutes per frame
in two-dimensional mode. Attenuation-corrected PET im-
ages (voxel size = 4.3 × 4.3 × 3.9 mm) were reconstructed
using the CT data by an ordered-subsets expectation
maximization algorithm (28 subsets, two iterations).
In the Discovery STE scanner, whole-body CT was per-
formed using a continuous spiral technique with a 16-slice
helical CT (140 kV, 30–170 mAs with an AutomA mode,
section width of 3.75 mm) 60 minutes after the injection
of FDG (5.5 MBq/kg). After the CT scans were complete,
emission scans were obtained from the thigh to the
head for 2.5 minutes per frame in three-dimensional (3D)
mode. Attenuation-corrected PET images (voxel size =
3.9 × 3.9 × 3.3 mm) were reconstructed using CT data by a
3D ordered-subsets expectation maximization algorithm
(20 subsets, two iterations). Commercial software (Advan-
tage Workstation; GE Healthcare) was used to accurately
coregister the separate CT and PET scan data.
Measurement of positron emission tomography/
computed tomography parameters
Semiquantitative and volumetric analyses were per-
formed using the PET VCAR software (GE Healthcare)
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which provides a convenient and automatic way to de-
lineate the volume of interest (VOI) using an isocontour
threshold method based on the SUV. We used a dy-
namic threshold SUV for determining the tumor bound-
ary, which was derived from a 2-cm rectangular VOI
placed at the right hepatic lobe (hepatic hilum level)
[28]. The average SUV (SUVavg) of the liver VOI plus
the two standard deviations (2 SDs) of each patient was
adopted as the threshold SUV. We measured the PET
parameters of all intrathoracic (lung, pleura, and medias-
tinum) malignant hypermetabolic lesions (Figure 1).
Benign FDG-avid lesions, such as inflammatory lung
lesions or reactive lymph nodes, were excluded from
quantitative analysis based on histopathologic results or
other imaging modalities. Using the above-mentioned
threshold SUV, the software automatically generated
the VOI of each hypermetabolic lesion and calculated
the various metabolic PET parameters, including the
maximum SUV (SUVmax), SUVavg, and MTV of each hy-
permetabolic lesion. Total TLG was calculated by multi-
plying the SUVavg by the MTV of each hypermetabolic
lesion. The highest SUVmax among the intrathoracic ma-
lignant hypermetabolic lesions, and the sum of the MTV
or TLG of all intrathoracic malignant hypermetabolic
lesions, were adopted as prognostic variables.
Treatment and clinical follow-up
None of the patients was surgically indicated. Patients
with LD underwent concurrent chemoradiotherapy, and
patients with ED underwent chemotherapy only as an
initial therapy. The chemotherapy regimen, consisting ofFigure 1 Representative coronal (a) and axial (b) positron emission to
showing automatically generated volumes of interest (VOIs) includinga platinum-based drug (cisplatin or carboplatin) with
either etoposide or irinotecan, was administered every
3 weeks for 4–6 cycles. Chest irradiation was initiated
on day 1 of the first or second cycle of chemotherapy
with 2.1 Gy once daily in 25 fractions. Patients showing
a complete response or partial response after chemora-
diotherapy received prophylactic cranial irradiation,
which consisted of 25 Gy in 10 fractions. The standard
response evaluation consisted of a chest X-ray prior to
each cycle and a chest CT every two cycles of chemo-
therapy. After completion of treatment, patients were
clinically followed up with a chest CT every 3 months
for 1 year, every 6 months in the following year, and
every 6–12 months thereafter.
Statistical analysis
Statistical analyses were performed using a commercial
software program, PASW Statistics 18 (IBM Corpor-
ation, Armonk, NY, USA). The main end point of sur-
vival prediction was overall survival. Overall survival
time was measured from the date of diagnosis to event
or last clinical follow-up. The event for overall survival
was defined as cancer- or treatment-related death. Sur-
vival curves were estimated using the Kaplan–Meier
estimator. Maximally selected log rank statistics were
used to determine the optimal cutoffs showing the best
discrimination of survival curves for continuous vari-
ables. Prognostic significance of the volumetric meta-
bolic PET parameters and other clinical variables were
assessed by univariate and multivariate analyses using
the Cox proportional hazards regression model, and an
estimated hazard ratio (HR) with a 95% confidencemography (PET) images of a patient with small-cell lung cancer
all malignant hypermetabolic intrathoracic lesions.
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sidered statistically significant.
Results
The demographic and clinical characteristics of the 202
patients are presented in Table 1. The median age was
64.0 ± 8.8 years (range, 39–87 years). Follow-up data were
available through to November 2011. At the time of ana-
lysis, 38 (19%) patients were still alive and 164 (81%) had
died. Median clinical follow-up time was 17.4 months,
with a range of 0–84 months. The median overall survival
was 14 months (95% CI, 12.4–15.6 months).
PET parameters for survival analysis included SUVmax,
SUVavg, sum of MTV, and the sum of TLG. For other
clinical parameters, gender, age, clinical stage (LD vs.
ED), treatment modality, performance status, serum al-
bumin, and LDH were also assessed. Treatment modal-
ities were categorized into chemotherapy alone and
chemotherapy plus radiotherapy. The mean ± the stand-
ard deviation of SUVmax, SUVavg, sum of MTV, and sum
of TLG were 11.8 ± 4.3, 5.1 ± 1.0, 150.4 ± 169.9 cm3, and
788.3 ± 826.5, respectively. According to the optimal cut-
off value for serum albumin (3.5 g/dl), LDH (480 IU/l),Table 1 Demographic and clinical characteristics of the
patients
Characteristics Number of patients (%)
Age (years)
< 65 100 (50)








Chemotherapy alone 117 (58)
Chemotherapy and radiotherapy 85 (42)
Performance status (ECOG)
0.1 181 (90)
≥ 2 21 (10)
Albumina
< 3.5 g/dl 31 (15)
≥ 3.5 g/dl 170 (85)
Lactate dehydrogenaseb
< 480 IU/l 111 (64)
≥ 480 IU/l 63 (36)
ECOG, Eastern Cooperative Oncology Group.
aOne missing data point.
b28 missing data points.SUVmax (12.0), SUVavg (5.0), sum of MTV (100 cm
3),
and sum of TLG (555), patients were divided into two
groups. The smaller MTV group consisted of 92 patients
and the larger MTV group of 110 patients; the smaller
TLG group consisted of 95 patients and the larger TLG
group of 107 patients.
On univariate analysis, age, clinical stage, treatment
modality, sum of MTV, and sum of TLG were significant
predictors of survival (Table 2). Figures 2, 3 and 4 show
the Kaplan–Meier curves for overall survival according
to clinical stage, sum of MTV, and sum of TLG, respect-
ively. In other words, old age, high clinical stage, chemo-
therapy only, high sum of MTV, and high sum of TLG
were associated with poor survival outcomes. There
were no significant differences in survival according
to gender, performance status, serum albumin, LDH,
SUVmax, or SUVavg. On multivariate analysis, age, clin-
ical stage, and sum of MTV were independent prognos-
tic factors (Table 3). Because there was a very high
correlation between the sum of MTV and the sum of
TLG (r = 0.963, P < 0.001), additional multivariate ana-
lysis was performed twice excluding the sum of MTV or
sum of TLG as a variable. The results revealed that both
sum of MTV (HR = 1.626, p = 0.003) or sum of TLG
(HR = 1.548, p = 0.007) was a significant independent
prognostic factor in each analysis.
Subgroup survival analysis was performed according
to the stage. In LD, only the sum of MTV and sum of
TLG were significant prognostic factors in the univariate
analysis (Table 4; Figures 5 and 6). There were no signifi-
cant differences in survival according to age, treatment
modality, gender, performance status, serum albumin,
LDH, SUVmax, or SUVavg. In ED, age was the only signifi-
cant prognostic factor in the univariate analysis (P < 0.001).
There were no significant differences in survival according
to treatment modality, gender, performance status, serum
albumin, LDH, SUVmax, SUVavg, sum of MTV (P = 0.071),
or sum of TLG (P = 0.081).
Discussion
Several SCLC studies have evaluated the prognostic sig-
nificance of FDG-PET. These studies suggested that high
SUVmax of the tumor and remaining FDG uptake after
treatment were poor prognostic factors [16-19]. Since
SUV is a semiquantitative index for FDG uptake of a
tumor, it gives one possibility for obtaining metabolic in-
formation. However, it remains unclear whether SUV is
an independent prognostic factor when compared with
stage [19,26]. In the current study, SUVmax was not a
significant independent prognostic factor for survival on
univariate analysis (P = 0.168). Our results are consistent
with those of previous reports that have found that
SUVmax is not an independent prognostic factor [19,26].
This can be partly explained by the partial volume effect
Table 2 Results of the univariate survival analysis
Variable HR 95% CI P
Age (1-year increase) 1.031 1.012–1.050 0.001
Clinical stage
Extensive (n = 107) vs. limited (n = 95) 2.446 1.761–3.397 < 0.001
Treatment modality
CTX only (n = 117) vs. CTX and RTX (n = 85) 2.181 1.573–3.023 < 0.001
Sum of MTV
10-cm3 increase 1.009 1.003–1.015 0.004
≥ 100 cm3 (n = 110) vs. < 100 cm3 (n = 92) 1.748 1.277–2.392 < 0.001
Sum of TLG
10-unit increase 1.002 1.001–1.004 0.001
≥ 555 (n = 107) vs. < 555 (n = 95) 1.697 1.242–2.318 0.001
HR, hazard ratio; CI, confidence interval; CTX, chemotherapy; RTX, radiotherapy; MTV, metabolic tumor volume; TLG, total lesion glycolysis.
Park et al. Cancer Imaging 2014, 14:2 Page 5 of 9
http://www.cancerimagingjournal.com/content/14/1/2and the dependence of SUVmax on tumor size. SUV is a
single voxel measurement, with the highest radiotracer
concentration within the VOI, and so it may not reflect
the heterogeneous nature of the tumor and it is easily
affected by statistical noise and voxel size [29]. Different
from SUVmax, which only represents single voxels, MTV
and TLG represent the extent of FDG uptake of the
whole tumor, and have been suggested as better prog-
nostic indicators than SUVmax for clinical outcomes in
other types of malignancies [20,25].
This is the largest study of volumetric PET parameters
as prognostic factors for survival in patients with SCLC
to date (202 patients). On univariate analysis, both the
sum of MTV and sum of TLG were significant prognos-
tic factors, along with age, clinical stage, and treatmentFigure 2 Kaplan–Meier curve for overall survival according to
clinical stage, which shows significantly worse outcomes in
extensive disease (ED) than in limited disease (LD) (median
survival, 12.0 ± 0.7 months vs. 19.0 ± 3.3 months, P < 0.001).modality. However, on multivariate analysis, only the
sum of MTV was an independent significant prognostic
factor along with age and clinical stage. When multivari-
ate analysis was performed twice including only either
the sum of MTV or sum of TLG because of high correl-
ation between MTV and TLG, the analysis revealed that
both were significant independent prognostic factors
with nearly the same HRs and P values. As the measure-
ment of MTV is simpler and MTV is a better independent
prognostic factor for survival as revealed on multivariate
analysis, the sum of MTV of the intrathoracic malignant
hypermetabolic lesions may be more suitable in routine
clinical practice for predicting survival prognosis in SCLC.
Zhu et al. [19] reported higher HR in MTV than in the
integrated SUV (iSUV, an analog to our TLG).Figure 3 Kaplan–Meier curve for overall survival according
to the sum of metabolic tumor volume (MTV) of malignant
hypermetabolic intrathoracic lesions, which shows significantly
worse outcomes in high MTV than in low MTV (median
survival, 12.0 ± 0.8 months vs. 18.0 ± 1.8 months, P < 0.001).
Figure 4 Kaplan–Meier curve for overall survival according
to the sum of total lesion glycolysis (TLG) of malignant
hypermetabolic intrathoracic lesions, which shows significantly
worse outcomes in high TLG than in low TLG (median survival,
12.0 ± 1.1 months vs. 18.0 ± 2.0 months, P = 0.001).
Table 4 Results of the univariate survival analysis in
limited disease
Variable HR 95% CI P
Sum of MTV
10-cm3 increase 1.025 0.999–1.050 0.055
≥ 100 cm3 (n = 45) vs. < 100 cm3 (n = 50) 1.779 1.072–2.959 0.036
Sum of TLG
10-unit increase 1.004 1.000–1.009 0.051
≥ 555 (n = 44) vs. < 555 (n = 51) 1.815 1.094–3.012 0.03
HR, hazard ratio; CI, confidence interval; MTV, metabolic tumor volume;
TLG, total lesion glycolysis.
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metric PET parameters were significant prognostic fac-
tors for survival in patients with LD, but not in patients
with ED, which may result from the higher event rate of
patient with ED (98%) compared to LD (64%). Therefore,
the volumetric PET parameters may be more useful as
prognostic factors in patients with LD rather than ED.
The median survival in LD with the high MTV (12.0 ±
1.1 months) and high TLG (12.0 ± 1.3 months) was
comparable to that of ED (12.0 ± 0.7 months). Thus,
the LD group with high metabolic parameters may be
treated differently from the group with low metabolic
parameters, and may deserve close follow-up for surveil-
lance. In other words, the LD group with high metabolic
parameters may be suggested to be treated as ED. A
further prospective study is warranted.
Zhu et al. [19] demonstrated that MTV and iSUV were
independent prognostic factors for survival in patients
with SCLC of not only intrathoracic malignant hyper-
metabolic lesions but also of extrathoracic malignant hy-
permetabolic lesions, while Oh et al. [26] demonstrated
that MTV is an independent prognostic factor for sur-
vival in patients with SCLC. They used an optimal cutoffTable 3 Results of the multivariate survival analysis
Variable HR 95% CI P
Age (1-year increase) 1.04 1.02–1.06 < 0.001
Clinical stage
Extensive vs. limited 2.442 1.742–3.425 < 0.001
Sum of MTV
≥ 100 cm3 vs. < 100 cm3 1.662 1.204–2.295 0.002
HR, hazard ratio; CI, confidence interval; MTV, metabolic tumor volume.of 127 cm3 or 64.6 cm3 for whole-body tumor MTV,
respectively, instead of our 100 cm3 for intrathoracic
tumor MTV. When those cutoffs of 127 cm3 and
64.6 cm3 were applied to our study, MTV was also a
significant prognostic factor for overall survival in spite
of different targets (P < 0.001 in both cutoffs).
These studies demonstrated the importance of volu-
metric PET parameters, such as MTV and TLG, as
prognostic factors, which is consistent with our study.
However, an important difference is that we investigated
only the volumetric PET parameters of intrathoracic
malignant hypermetabolic lesions. Autopsy and clinical
studies have shown that SCLC can involve multiple sites,
including intra-abdominal lesions: liver, adrenal glands,
and retroperitoneal lymph nodes, and less frequently, the
pancreas, spleen, and kidneys (incidence at presentation =
35%); bone (incidence at presentation = 27–41%); bone
marrow (incidence at presentation = 15–30%); brain (inci-
dence at presentation = 10–14%); and subcutaneous softFigure 5 Kaplan–Meier curve for overall survival according
to the sum of metabolic tumor volume (MTV) of malignant
hypermetabolic intrathoracic lesions in limited disease (LD),
which shows significantly worse outcomes in high MTV than
in low MTV (median survival, 12.0 ± 1.1 months vs. 25.0 ±
4.9 months, P = 0.036).
Figure 6 Kaplan–Meier curve for overall survival according to the sum of total lesion glycolysis (TLG) of malignant hypermetabolic
intrathoracic lesions in limited disease (LD), which shows significantly worse outcomes in high TLG than in low TLG (median survival;
12.0 ± 1.3 months vs. 28.0 ± 4.0 months, P = 0.03).
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FDG uptake [31]. Therefore, it may be challenging to accur-
ately measure volumetric PET parameters of extrathoracic
malignant hypermetabolic lesions using a threshold-based
cutoff SUV for delineating the boundaries of the lesions.
On the other hand, it is relatively easy to accurately meas-
ure volume-based PET parameters of intrathoracic lesions
using a cutoff SUV of liver activity. In addition, the meas-
urement of PET parameters including all malignant
hypermetabolic lesions may be time-consuming and not
available in routine clinical practice. Therefore, it would
be advantageous if the PET parameters from intrathoracic
lesions only could provide useful prognostic information.
The results of our study support this hypothesis. Our
results suggest that the volumetric PET parameters of
FDG-PET/CT have an important role in predicting prog-
nosis and making risk-adapted therapeutic decisions in
patients with SCLC. For example, in a higher MTV group
expecting worse prognosis, closer clinical follow-up for
surveillance and participation in clinical trials may be
considered.
A standardized method for determining SUV thresh-
olds to estimate tumor boundaries has not yet been
established. We used a relative SUV threshold for deter-
mining the tumor boundary, SUVavg of the liver plus the
2 SDs of each patient, which is different from recent
reports [19,26]. One study used a single, fixed SUV
threshold of 2.5, while another applied a single, fixed
SUV threshold of 3.0. SUV can be affected by many
factors, including tumor characteristics, VOI definition,partial volume effect, image resolution, reconstruction
methods, noise, time between tracer injection and im-
aging, attenuation correction, normalization factor, and
plasma glucose level [29,32]. Therefore, we presumed
that using the same fixed threshold SUV for different pa-
tients might have limitations. Comparing tumor activity
to background activity is an attractive way to minimize
variability and to potentially ensure the quality of scans
from test to retest. A variety of backgrounds have been
used, including the thighs, back muscles, liver, and medi-
astinum. Paquet et al. [33] showed that liver SUV is
stable over time, when measured centrally as a mean on
a single slice in the right lobe of the liver. Thus, we used
a relative threshold of SUV for each patient according to
the SUV of the liver, which is similar to a previous study
[25]. In addition, in the PET Response Criteria in Solid
Tumors framework, the SUV of the liver is used as the
reference organ [28].
The present study has several limitations. First, be-
cause it was a retrospective study, some medical records,
such as serum albumin and LDH, were missing in some
patients, and it was also difficult to evaluate accurate
performance status at the initial stage. Second, not all
concerned intrathoracic hypermetabolic lesions were
histopathologically confirmed, but the findings of follow-
up studies were used for confirming malignancy. Third,
a possible limitation was the use of two different kinds of
scanners and acquisition protocols, and the accompanying
uncertainty of whether or not the volumetric PET parame-
ters were consistent between the two scanners. However,
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clinical indicators, and disease severity of patients accord-
ing to the scanner type. For the survival analysis, when
applying the same cutoffs of metabolic parameters for pri-
mary tumors in subgroups according to scanner type, both
sum of MTV and sum of TLG were significant prognostic
factors in all subgroups like all patients group. Therefore,
we suggest that this issue may not significantly affect our
results. Finally, the present study lacks a 2-cohort cross-
validation for the cutoff values of quantitative PET prog-
nostic biomarkers to avoid bias, due to the relatively small
number of subjects. Therefore, this is a kind of exploratory
study.
Conclusions
In conclusion, the sums of MTV and TLG of the intra-
thoracic malignant hypermetabolic lesions, volumetric
metabolic parameters of FDG-PET/CT, are important
independent prognostic factors for survival in addition
to age and clinical stage. Volumetric metabolic parame-
ters may be more useful as prognostic factors in patients
with SCLC of LD rather than of ED. However, a further,
well-designed, confirmatory validation study with a stan-
dardized protocol is necessary.
Competing interests
This study was supported by a grant from the National R&D Program for
Cancer Control, Ministry of Health and Welfare, Republic of Korea (#1120150).
Authors’ contributions
All authors carried out the study concepts and design, literature research,
data analysis, study analysis, manuscript preparation and editing. All authors
read and approved the final manuscript.
Author details
1Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan
University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul 135-710,
Korea. 2Division of Pulmonary and Critical Care, Department of Medicine,
Samsung Medical Center, Sungkyunkwan University School of Medicine,
Seoul, Korea. 3Department of Radiation Oncology, Samsung Medical Center,
Sungkyunkwan University School of Medicine, Seoul, Korea. 4Division of
Hemato-Oncology, Department of Medicine, Samsung Medical Center,
Sungkyunkwan University School of Medicine, Seoul, Korea.
Received: 6 March 2014 Accepted: 6 March 2014
Published: 22 April 2014
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer
statistics. CA Cancer J Clin 2011, 61:69–90.
2. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A,
Spitznagel EL, Piccirillo J: Changing epidemiology of small-cell lung cancer
in the United States over the last 30 years: analysis of the surveillance,
epidemiologic, and end results database. J Clin Oncol 2006, 24:4539–4544.
3. Simon GR, Wagner H: American College of Chest Physicians. Small cell
lung cancer. Chest 2003, 123(1 Suppl):259S–271S.
4. Yip D, Harper PG: Predictive and prognostic factors in small cell lung
cancer: current status. Lung Cancer 2000, 28:173–185.
5. Micke P, Faldum A, Metz T, Beeh KM, Bittinger F, Hengstler JG, Buhl R:
Staging small cell lung cancer: veterans administration lung study group
versus international association for the study of lung cancer—what
limits limited disease? Lung Cancer 2002, 37:271–276.6. Thomson D, Hulse P, Lorigan P, Faivre-Finn C: The role of positron
emission tomography in management of small cell lung cancer.
Lung Cancer 2011, 73:121–126.
7. Arinc S, Gonlugur U, Devran O, Erdal N, Ece F, Ertugrul M, Derince D,
Oruc O, Hazar A: Prognostic factors in patients with small cell lung
carcinoma. Med Oncol 2010, 27:237–241.
8. Brink I, Schumacher T, Mix M, Ruhland S, Stoelben E, Digel W, Henke M,
Ghanem N, Moser E, Nitzsche EU: Impact of [18F]FDG-PET on the primary
staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 2004,
31:1614–1620.
9. Azad A, Chionh F, Scott AM, Lee ST, Berlangieri SU, White S, Mitchell PL: High
impact of 18F-FDG-PET on management and prognostic stratification of
newly diagnosed small cell lung cancer. Mol Imaging Biol 2010, 12:443–451.
10. Fischer BM, Mortensen J, Langer SW, Loft A, Berthelsen AK, Petersen BI,
Daugaard G, Lassen U, Hansen HH: A prospective study of PET/CT in initial
staging of small-cell lung cancer: comparison with CT, bone scintigraphy
and bone marrow analysis. Ann Oncol 2007, 18:338–345.
11. Bradley JD, Dehdashti F, Mintun MA, Govindan R, Trinkaus K, Siegel BA:
Positron emission tomography in limited-stage small-cell lung cancer:
a prospective study. J Clin Oncol 2004, 22:3248–3254.
12. Kamel EM, Zwahlen D, Wyss MT, Stumpe KD, von Schulthess GK, Steinert
HC: Whole-body (18)F-FDG PET improves the management of patients
with small cell lung cancer. J Nucl Med 2003, 44:1911–1917.
13. Kut V, Spies W, Spies S, Gooding W, Argiris A: Staging and monitoring of
small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron
emission tomography (FDG-PET). Am J Clin Oncol 2007, 30:45–50.
14. Vinjamuri M, Craig M, Campbell-Fontaine A, Almubarak M, Gupta N, Rogers
JS: Can positron emission tomography be used as a staging tool for
small-cell lung cancer? Clin Lung Cancer 2008, 9:30–34.
15. Yamamoto Y, Kameyama R, Murota M, Bandoh S, Ishii T, Nishiyama Y: Early
assessment of therapeutic response using FDG PET in small cell lung
cancer. Mol Imaging Biol 2009, 11:467–472.
16. Pandit N, Gonen M, Krug L, Larson SM: Prognostic value of [18F]FDG-PET
imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging 2003, 30:78–84.
17. Onitilo AA, Engel JM, Demos JM, Mukesh B: Prognostic significance of
18F-fluorodeoxyglucose - positron emission tomography after treatment
in patients with limited stage small cell lung cancer. Clin Med Res 2008,
6:72–77.
18. Lee YJ, Cho A, Cho BC, Cho BC, Yun M, Kim SK, Chang J, Moon JW, Park IK,
Choi HJ, Kim JH: High tumor metabolic activity as measured by
fluorodeoxyglucose positron emission tomography is associated with
poor prognosis in limited and extensive stage small-cell lung cancer.
Clin Cancer Res 2009, 15:2426–2432.
19. Zhu D, Ma T, Niu Z, Zheng J, Han A, Zhao S, Yu J: Prognostic significance
of metabolic parameters measured by (18)F-fluorodeoxyglucose positron
emission tomography/computed tomography in patients with small cell
lung cancer. Lung Cancer 2011, 73:332–337.
20. Kim BS, Kim IJ, Kim S-J, Nam H-Y, Pak KJ, Kim K, Yun MS: The prognostic
value of the metabolic tumor volume in FIGO stage IA to IIB cervical
cancer for tumor recurrence: measured by F-18 FDG PET/CT. Nucl Med
Mol Imaging 2011, 45:36–42.
21. Moon SH, Choi JY, Lee HJ, Son YI, Baek CH, Ahn YC, Park K, Lee KH, Kim BT:
Prognostic value of 18F-FDG PET/CT in patients with squamous cell
carcinoma of the tonsil: comparisons of volume-based metabolic
parameters. Head Neck 2013, 35:15–22.
22. Choi K-H, Yoo IR, Han EJ, Kim YS, Kim GW, Na SJ, Sun D-I, Jung SL, Jung C-K,
Kim M-S, Lee S-Y, Kim SH: Prognostic value of metabolic tumor volume
measured by 18F-FDG PET/CT in locally advanced head and neck squamous
cell carcinomas treated by surgery. Nucl Med Mol Imaging 2011, 45:43–51.
23. Basaki K, Abe Y, Aoki M, Kondo H, Hatayama Y, Nakaji S: Prognostic factors
for survival in stage III non-small-cell lung cancer treated with definitive
radiation therapy: impact of tumor volume. Int J Radiat Oncol Biol Phys
2006, 64:449–454.
24. Hyun SH, Choi JY, Shim YM, Kim K, Lee SJ, Cho YS, Lee JY, Lee KH,
Kim BT: Prognostic value of metabolic tumor volume measured by
18F-fluorodeoxyglucose positron emission tomography in patients
with esophageal carcinoma. Ann Surg Oncol 2010, 17:115–122.
25. Lee HY, Hyun SH, Lee KS, Kim BT, Kim J, Shim YM, Ahn MJ, Kim TS, Yi CA,
Chung MJ: Volume-based parameter of 18F-FDG PET/CT in malignant
pleural mesothelioma: prediction of therapeutic response and
prognostic implications. Ann Surg Oncol 2010, 17:2787–2794.
Park et al. Cancer Imaging 2014, 14:2 Page 9 of 9
http://www.cancerimagingjournal.com/content/14/1/226. Oh JR, Seo JH, Chong A, Min JJ, Song HC, Kim YC, Bom HS: Whole-body
metabolic tumour volume of 18F-FDG PET/CT improves the prediction
of prognosis in small cell lung cancer. Eur J Nucl Med Mol Imaging 2012,
39:925–935.
27. Yoo J, Choi JY, Lee KT, Son YI, Baek CH, Ahn YC, Park K, Lee KH, Kim BT:
Prognostic significance of volume-based metabolic parameters
by 18F-FDG PET/CT in gallbladder carcinoma. Nucl Med Mol Imaging
2012, 46:201–206.
28. Wahl RL, Jacene H, Kasamon Y, Lodge MA: From RECIST to PERCIST:
evolving considerations for PET response criteria in solid tumors.
J Nucl Med 2009, 50(Suppl 1):122S–150S.
29. Soret M, Bacharach SL, Buvat I: Partial-volume effect in PET tumor
imaging. J Nucl Med 2007, 48:932–945.
30. Argiris A, Murren JR: Staging and clinical prognostic factors for small-cell
lung cancer. Cancer J 2001, 7:437–447.
31. Kostakoglu L, Hardoff R, Mirtcheva R, Goldsmith SJ: PET-CT fusion imaging
in differentiating physiologic from pathologic FDG uptake. Radiographics
2004, 24:1411–1431.
32. Westerterp M, Pruim J, Oyen W, Hoekstra O, Paans A, Visser E, van Lanschot J,
Sloof G, Boellaard R: Quantification of FDG PET studies using standardised
uptake values in multi-centre trials: effects of image reconstruction,
resolution and ROI definition parameters. Eur J Nucl Med Mol Imaging
2007, 34:392–404.
33. Paquet N, Albert A, Foidart J, Hustinx R: Within-patient variability of
(18)F-FDG: standardized uptake values in normal tissues. J Nucl Med
2004, 45:784–788.
doi:10.1186/1470-7330-14-2
Cite this article as: Park et al.: Prognostic value of volumetric metabolic
parameters measured by [18F]Fluorodeoxyglucose-positron emission
tomography/computed tomography in patients with small cell lung
cancer. Cancer Imaging 2014 14:2.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
